Pharmaceutical company Sanofi has begun construction on a new insulin production facility in Frankfurt, committing an investment of approximately two billion euros. The new plant is designed to replace an existing insulin facility, secure supplies for diabetic patients across Germany and Europe, and safeguard thousands of jobs. Spanning 36,000 square meters—equivalent to about five football fields—the facility will meet advanced standards and utilize artificial intelligence. Upon its scheduled commissioning in 2032, the plant will rank among the largest insulin production sites in Europe and play a crucial role in Sanofi's global insulin supply network.
Chief Executive Officer Belen Garijo stated at the ground-breaking ceremony in the Frankfurt Höchst industrial park that millions of people globally rely on insulin daily, and the coronavirus pandemic demonstrated the vulnerability of medical supplies. Sanofi originally announced the construction project in 2024. In September, the European Commission approved state aid amounting to 400 million euros, provided jointly by the federal government, the state of Hesse, and the city of Frankfurt. Previous disclosures indicate that the new facility will initially produce at least 1.1 tonnes of insulin annually. Furthermore, Sanofi is required to stockpile one tonne of active pharmaceutical insulin ingredients and prioritize European markets in the event of an insulin supply bottleneck.
Hesse's Minister-President Boris Rhein noted that the project contributes to security of supply in Europe, strengthens European sovereignty, and reduces dependencies on third countries. Diabetes mellitus causes elevated blood sugar levels, as the hormone insulin enables the absorption of glucose from the blood into body cells. According to Sanofi figures, diabetes affects more than 500 million people worldwide, a total that could climb to 800 million by 2050. Earlier European Union statements indicated that without state aid, Sanofi would have closed its German site. The location is the sole production facility for human insulin within the European Economic Area alongside one other operated by pharmaceutical company Novo Nordisk in Denmark.
The long-standing insulin production is vital for the Frankfurt location, supporting more than 4,000 of the 6,500 jobs at Sanofi in Frankfurt-Höchst. The site supplies approximately 15 million patients across roughly 80 countries with insulin products, covering the entire value chain from active ingredient manufacturing, filling, and the production of pens and auto-injectors to packaging. Frankfurt's Lord Mayor Mike Josef described the investment as an extremely important signal for Frankfurt as a pharmaceutical and industrial hub, adding that the city will continue to support the project with all its strength.
